A coordinated group of investment funds and individuals associated with Kymera Therapeutics, Inc. (NASDAQ: KYMR) reported the liquidation of common stock valued at approximately $173.7 million on June 26, 2026. The reported transactions involved the disposition of 1,630,658 shares of the company's common equity. All shares were executed at a fixed price of $106.50 per share. Following the completion of these sales, the affiliated funds and associated accounts continue to hold a substantial ownership stake in Kymera Therapeutics.
The reporting entity includes Mark N. Lampert, who is classified as a director by deputization of Kymera Therapeutics, Inc. This designation arises from Gorjan Hrustanovic, a member of BVF Partners L.P., serving on the issuer’s board of directors and operating under an agreement to transfer the economic benefit from certain securities to the partnership. Other entities involved in the transaction include Biotechnology Value Fund, L.P., and Biotechnology Value Fund II, L.P.
After the reported sales, the various affiliated entities collectively hold 3,872,052 shares of common stock. Additionally, the group holds pre-funded warrants to purchase 1,365,099 shares of common stock, exercisable at $0.0001 per share with no expiration date. The group also maintains stock options to acquire an aggregate of 122,258 shares of common stock at various exercise prices and expiration dates, with most of these options being fully vested.
The sale activity follows a period of significant price appreciation for Kymera Therapeutics. The stock has surged 136% over the past year, currently trading at $108. According to InvestingPro analysis, the company appears overvalued relative to its Fair Value, placing it among the most overvalued stocks tracked by the platform. The stock carries a high Price/Book multiple of 6.24, while the company remains unprofitable with a market cap of $8.87 billion.
In other recent developments, Kymera Therapeutics has made significant progress in its clinical trials. The company completed enrollment in its Phase IIb BROADEN2 study for KT-621, an oral STAT6 degrader for atopic dermatitis, nearly six months ahead of schedule. This development has allowed Kymera to advance the expected topline data release to year-end 2026, earlier than the previous mid-2027 guidance. As a result, Canaccord Genuity raised its price target for Kymera to $129, while B.Riley increased its target to $155, with both firms maintaining a Buy rating on the stock. In another development, Kymera announced that Felix J. Baker has been appointed as the new Chairman of the Board of Directors, succeeding Bruce Booth, who will remain as an Independent Director.